Last reviewed · How we verify
Anti-OX40 Antibody PF-04518600 (anti-ox40-antibody-pf-04518600)
PF-04518600 is an anti-OX40 antibody developed by Pfizer Inc. It is marketed for the treatment of non-small cell lung cancer and hepatocellular carcinoma. The drug has undergone 8 clinical trials but has no publications. Its commercial significance and pipeline developments are not specified. PF-04518600 is a monoclonal antibody targeting the OX40 receptor. The drug's mechanism of action is not detailed. It is a novel treatment option for patients with these indications.
At a glance
| Generic name | anti-ox40-antibody-pf-04518600 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal antibody |
| Target | OX40 receptor |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
- Hepatocellular carcinoma
Common side effects
Drug interactions
- Warfarin
- Aspirin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
Key clinical trials
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (PHASE2)
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (PHASE1, PHASE2)
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (PHASE3)
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (PHASE2)
- Rituximab + Immunotherapy in Follicular Lymphoma (PHASE1)
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (PHASE1, PHASE2)
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-OX40 Antibody PF-04518600 CI brief — competitive landscape report
- Anti-OX40 Antibody PF-04518600 updates RSS · CI watch RSS
- Pfizer portfolio CI